Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MDS according to protocol-specified criteria via bone marrow studies performed within 12 weeks before randomization~Exclusion Criteria:~* No prior or concurrent treatment with epoetin alfa or any other approved or experimental erythropoietin stimulating agents (ESAs) within the previous 12 months before randomization~* No prior use of approved or experimental agents for the treatment of MDS or recent treatment with granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) for the treatment of neutropenia~* Patients must not have secondary MDS or anemia caused by factors other than MDS (including iron deficiency, vitamin B12 or folate deficiencies, hemolysis, chronic renal failure, or gastrointestinal bleeding)~* No history (within 12 months) of deep venous thrombosis~* or history (within 6 months) of stroke, acute coronary syndrome or other arterial thrombosis~* Not currently receiving therapeutic anticoagulants or have uncontrolled hypertension~* No uncontrolled disease or dysfunction deemed clinically significant by the Investigator not attributable to MDS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Epoetin alfa 40 000 IU subcutaneously once every week (1 mL dose) for 48 weeks
- 002 (Type: EXPERIMENTAL): Epoetin alfa 80 000 IU subcutaneously once every week (2 mL dose) for 48 weeks
- 003 (Type: PLACEBO_COMPARATOR): Placebo Matching volume 1 mL for 48 weeks
- 004 (Type: PLACEBO_COMPARATOR): Placebo Matching volume 2 mLfor 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).